Clinical trials: Disorders of Excessive Somnolence
Narcolepsy, Narcolepsy 1
'A Profile of Physical Performance Variables in an Out-patient Adult Population With Narcolepsy'
Narcolepsy is a sleep disorder characterised by excessive daytime sleepiness and significantly impacts quality of life. People with narcolepsy demonstrate many potential barriers to being physically active, such as sleepiness and…
- Conditions
- Narcolepsy, Narcolepsy 1, Narcolepsy Type 1, Narcolepsy With Cataplexy
- Trial name
- NCT04419792
- Testing
- Assessment of physical performance variables
- Where
- Ireland
- Volunteers
- 70 people
- Sponsor
- University of Dublin, Trinity College
Hypersomnia, Narcolepsy
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
The study evaluates whether the use of Sodium Oxybate (Xyrem®) in TBI patients will be effective in reducing symptoms of post traumatic narcolepsy and post traumatic hypersomnia.
- Conditions
- Hypersomnia, Narcolepsy, Traumatic Brain Injury
- Trial name
- NCT03626727
- Testing
- Sodium Oxybate Oral Solution [Xyrem]
- Where
- United States
- Sponsor
- Brigham and Women's Hospital
Excessive Daytime Sleepiness
Alternative Epworth Sleepiness Scale ESS-ALT in French
The Epworth Sleepiness Scale (ESS) is undoubtedly the most commonly used tool in daily clinical practice to assess daytime sleepiness in patients of all ages by means of a self-administered questionnaire.
- Trial name
- SOMNOLD (NCT05822128)
- Testing
- Test of an alternative Epworth Sleepiness Scale ESS-ALT in French
- Where
- 2 sites in France
- Volunteers
- 102 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Apnea, Sleep Disorders
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
This study is being done to learn about the safety and effects of a study medicine called berobenatide (bear-oh-BEN-uh-tide). The study will see if berobenatide can help adults with breathing problems during sleep (obstructive…
- Conditions
- Apnea, Sleep Disorders, Overweight and/or Obesity
- Trial name
- VESPER-OSA 2 (NCT07881757)
- Testing
- Berobenatide
- Where
- 2 sites in United States
- Volunteers
- 258 people
- Sponsor
- Pfizer
Parkinson's Disease
Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease
To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649 in the improvement of excessive daytime…
- Trial name
- HARPS2 (NCT01066442)
- Testing
- BF2.649 (Pitolisant)
- Where
- Germany
- Volunteers
- 273 people
- Sponsor
- Bioprojet
Daytime Sleepiness
Community-Level Daytime Sleepiness: Social-Environmental Determinants, Consequences, and Impact of Sleep Apnea
The purpose of this study is to examine daytime sleepiness in a community context. This includes examining sleepiness in a large sample in terms of social/behavioral/environmental predictors and health-related outcomes, as well…
- Trial name
- NCT04176042
- Testing
- Track 1, Track 2
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Sleep Disorders, Obstructive Sleep Apnea
Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea…
- Conditions
- Sleep Disorders, Obstructive Sleep Apnea, Major Depressive Disorder, Dysthymic Disorder
- Trial name
- NCT00518986
- Testing
- armodafinil
- Where
- 62 sites in United States
- Volunteers
- 249 people
- Sponsor
- Cephalon
Sleep Disorders
Patient Preference, Sleep Quality, and Anxiety/Depression: A Randomized Comparison of Etravirine and Efavirenz
Efavirenz causes neuropsychiatric side effects and sleep disturbance, including vivid dreams, dizziness, and abnormal tiredness.
- Trial name
- SWITCH-EE (NCT00792584)
- Testing
- etravirine, efavirenz
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Geneva
Healthy, Narcolepsy
A Study of MK-6552 in Sleep Deprived Healthy Participants (MK-6552-003)
This study examined the safety of the drug MK-6552 and if people tolerated it. It also studied whether MK-6552 works better than placebo for staying awake in sleep deprived healthy participants.
- Trial name
- NCT06619665
- Testing
- MK-6552, Modafinil
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypersomnia, Narcolepsy
Sleep Disorders of Patients With Diseases of the Nervous System
The purpose of this study is to assist training doctors about different diseases of the nervous system affecting sleep. Patients selected to participate in this study will have any of a variety of sleep disorders.
- Conditions
- Hypersomnia, Narcolepsy, Nervous System Disease, Sleep Disorder
- Trial name
- NCT00001664
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Sleep Disorder
Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ABT-652 in Subjects With Excessive Daytime Sleepiness
The main purpose of this study is to evaluate the safety and tolerability of the drug ABT-652 given once daily to people with excessive daytime sleepiness.
- Trial name
- NCT01124851
- Testing
- ABT-652
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Abbott
Excessive Daytime Sleepiness, Narcolepsy
Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome
The purpose of this study is to assess patient reported outcomes with armodafinil treatment in terms of improvement in sleepiness, satisfaction with treatment, impact on ability to engage in life activities (ie, daily or work and…
- Conditions
- Excessive Daytime Sleepiness, Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)
- Trial name
- NCT00228566
- Testing
- Armodafinil
- Where
- 43 sites in United States
- Volunteers
- 247 people
- Sponsor
- Cephalon
Shift Work
Effects of Operational Naps on Blood Pressure and Performance Among Night Shift Workers
Night shift work schedules disrupt sleep and have a negative impact on cardiovascular health. Most who work in public safety occupations and in healthcare work night shifts.
- Trial name
- EONN (NCT07217769)
- Testing
- No-nap, 15-min nap, 30-min nap
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Obstructive Sleep Apnea, Vascular Stiffness
CPAP to Reduce Arterial Stiffness in Non Sleepy, Moderate to Severe Obstructive Sleep Apnea (STIFFSLEEP)
This study intends to determine whether continuous positive airway pressure (CPAP) can reduce arterial stiffness (measured by pulse wave velocity) in nonsleepy as well as in sleepy patients with obstructive sleep apnea .
- Conditions
- Obstructive Sleep Apnea, Vascular Stiffness, Sleep Disorder Daytime Somnolence
- Trial name
- STIFFSLEEP (NCT02273089)
- Testing
- CPAP (ResMed S9 AutoSet)
- Where
- 2 sites in Portugal
- Volunteers
- 45 people
- Sponsor
- Centro Hospitalar de Lisboa Central
Narcolepsy
Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy
The study is planned to provide expanded access treatment to subjects with narcolepsy who have completed the 2-week treatment phase and follow-up in study CTP2S13031H3 (NCT04072380), and in instances when the investigator as well…
- Trial name
- NCT05530447
- Testing
- Samelisant
- Sponsor
- Suven Life Sciences Limited
Idiopathic Hypersomnia, Narcolepsy Type 1 (NT 1)
A Novel Approach to Manage Symptoms of Narcolepsy and Idiopathic Hypersomnia
The aim of this project is to learn about how a change in diet will affect sleepiness, quality of life and metabolic health in people living with narcolepsy and idiopathic hypersomnia.
- Conditions
- Idiopathic Hypersomnia, Narcolepsy Type 1 (NT 1), Narcolepsy Type 2 (NT2)
- Trial name
- COMPANION (NCT07006233)
- Testing
- Whole Food Ketogenic Diet, Whole Food Diet
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- University of Sydney
Upper Airway Resistance Syndrome
Efficacy of Oral Appliance for Upper Airway Resistance Syndrome
Introduction: The Upper Airway Resistance Syndrome (UARS) is a sleep disorder characterized by airway resistance to breathing during sleep that leads to arousals and daytime sleepiness.
- Trial name
- NCT02636621
- Testing
- Brazilian Dental Appliance
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Associação Fundo de Incentivo à Pesquisa
Narcolepsy Type 1, Narcolepsy With Cataplexy
A Eight-Week Study of NLS-2 (Mazindol Extended Release) in Participants With Narcolepsy Type 1
The goal of this clinical trial is to see how NLS-2 (mazindol extended-release) works on symptoms of narcolepsy, including cataplexy and excessive daytime sleepiness.
- Trial name
- AMAZE (NCT05914194)
- Testing
- NLS-2
- Volunteers
- 48 people
- Sponsor
- NLS Pharmaceutics
Abdominal Obesity
Effects of Weight Reduction on Sleep and Alertness in Long-distance Truck and Bus Drivers
The study is a year-long health-behaviour intervention in obese, male truck-drivers to lose weight moderately by 10%, using monthly individual counseling.
- Trial name
- SF-Truck (NCT00893646)
- Testing
- weight loss counseling
- Where
- 3 sites in Finland
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- UKK Institute
Dystrophia Myotonica 1
Methylphenidate in Myotonic Dystrophy Type 1
The purpose of this study is to determine whether methylphenidate is effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1).
- Trial name
- NCT01421992
- Testing
- Methylphenidate
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- Laval University